Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.25 USD | -1.75% | -8.20% | -29.25% |
May. 15 | Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA | CI |
May. 15 | Lumos Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Evolution of the average Target Price on Lumos Pharma, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Lumos Pharma, Inc.
Oppenheimer | |
Cantor Fitzgerald | |
Jefferies & Co. | |
Roth Capital Partners | |
HC Wainwright | |
JonesTrading Institutional Services | |
Stifel Nicolaus |
EPS Revisions
- Stock Market
- Equities
- LUMO Stock
- Consensus Lumos Pharma, Inc.